New Triple-Threat treatment tested for blood cancer
NCT ID NCT00378105
Summary
This study tested a combination of three drugs—bortezomib, lenalidomide, and dexamethasone—for people newly diagnosed with multiple myeloma, a cancer of plasma cells. The main goals were to find the safest dose of the drug combination and to see how well it worked to control the disease. The study involved 68 participants who had not received any prior treatment for their myeloma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.